Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma 2Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 15Cisplatin 13pembrolizumab 6Platinum 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Radiotherapy 3Gemcitabine 3Carboplatin 3amatuximab 2Radiotherapy, Intensity-Modulated 2Radiation 2Everolimus 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1sodium thiosulfate 1sargramostim 1nintedanib 1napabucasin 1methoxyamine 1liposomal doxorubicin 1incomplete Freund's adjuvant 1fresolimumab 1durvalumab 1defactinib 1cixutumumab 1bintrafusp alfa protein, human 1bemcentinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mesothelioma, Malignant × anetumab ravtansine × Clear all
NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
49 enrolled 20 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡